ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

#AUA14 - Sipuleucel-T-induced antigen spread: immune response to prostate-specific antigen correlates with improved overall survival - Session Highlights

ORLANDO, FL USA (UroToday.com) - Sipuleucel-T is a prostatic acid phosphatase-targeting immunotherapy approved for treatment of asymptomatic or minimally symptomatic, metastatic castration-resistant prostate cancer (mCRPC). Immunotherapy-induced tumor cell death may lead to release of secondary tumor antigens which can generate downstream immune responses. This “antigen spread” may contribute to tumor control and reveal post-treatment biomarkers of use in determining clinical outcomes. Dr. Simon Hall and colleagues presented data evaluating antigen spread to prostate antigens (PSA, PSMA, and hK2/KLK2) following sipuleucel-T treatment and the association of antigen spread with overall survival.

auaPatients from the IMPACT (n=202) and ProACT (n=33) trials were evaluated for antigen spread following sipuleucel-T treatment (based on IgG levels). In both cohorts, there was evidence of antigen spread, with elevated IgG antibodies against PSA (≥ 25%), PSMA (≥ 18%), and hK2 (≥ 33%). Following multivariable adjustment for baseline PSA, LDH, bone lesions, Gleason score, and prior bisphosphonate use, IgG response against PSA was positively correlated with improved overall survival. Median overall survival was not reached (> 33 months) in patients with IgG response to PSA compared to 22 months in patients with no antigen spread. There was no association between IgG responses to PSMA and hK2 and overall survival.

Antigen spreading appears to mediate adaption of the immune response to target multiple prostate antigens following sipuleucel-T treatment. Sipuleucel-T-induced IgG responses against PSA were predictive of overall survival and may be a potential biomarker of treatment benefit.

Presented by Simon J Hall, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Icahn School of Medicine at Mount Sinai, New York, NY USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe